Stéphane L.
- Country
- France
- Department
- Département d'Hématologie
Research Overview
- Dose-Escalation and Expansion Study of BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein Degrader, in Patients with B-Cell Malignancies
- Phase 2 Study on Zanubrutinib and BGB-11417 Efficacy and Tolerance in Previously Treated Waldenström Macroglobulinemia Patients
- Efficacy and Safety Comparison of Obinutuzumab-Venetoclax vs. Obinutuzumab-Chlorambucil in Untreated CLL with Comorbidities
Data & Insights
Has run more than one trial at 143 of 296 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular emphasis on novel therapeutic approaches for both treatment-naïve and previously treated patients.
- BTK Inhibitor Therapies
- Venetoclax-based Combinations
- Targeted Immunotherapies
Focuses on developing treatment strategies for high-risk CLL patients and those with coexisting medical conditions.
Advanced Therapeutics
Explores innovative treatment combinations involving bispecific antibodies and protein degraders for B-cell malignancies, including specialized approaches for Richter's syndrome.
- Novel Drug Combinations
- Fixed-Duration Therapies
- MRD-Guided Treatment
Investigates treatment optimization through duration-adjusted therapeutic regimens.
Specialized Conditions
Conducts research in rare and complex hematological conditions, including Waldenström macroglobulinemia and transformed lymphomas.
- Disease Transformation Studies
- Elderly Patient Care
- Treatment-Resistant Cases
Addresses specific therapeutic needs of elderly patients and those with high-risk disease features.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.